公开(公告)号：US08642552B2

公开(公告)日：2014-02-04

申请号：US12443837

申请日：2007-10-01

申请人： Jose Ignacio Fernandez Montequin ,  Luis Saturnino Herrera Martinez ,  Jorge Amador Berlanga Acosta ,  Diana Garcia Del Barco Herrera ,  Danay Cibrian Vera ,  Gerardo Enrique Guillen Nieto ,  Raimundo Ubieta Gomez ,  Sonia Gonzalez Blanco ,  Vivian Maria Saez Martinez

发明人： Jose Ignacio Fernandez Montequin ,  Luis Saturnino Herrera Martinez ,  Jorge Amador Berlanga Acosta ,  Diana Garcia Del Barco Herrera ,  Danay Cibrian Vera ,  Gerardo Enrique Guillen Nieto ,  Raimundo Ubieta Gomez ,  Sonia Gonzalez Blanco ,  Vivian Maria Saez Martinez

IPC分类号： A61P25/02 ,  A61K38/18 ,  C07K14/485

CPC分类号： A61K38/1808 ,  A61K9/16 ,  C07K14/485 ,  Y10S930/12

摘要： The invention relates to human medicine and to the use of epidermal growth factor (EGF) for preparing a pharmaceutical composition which is administered by infiltration into the periphery of nerve ganglia and/or trunks for the morphofunctional restoration of peripheral nerves in painful sensory-motor neuropathy as well as manifestations of ischemic neuritis. The invention also includes a composition containing EGF which can be formulated together with anesthetics or analgesics or encapsulated in microspheres and to the use thereof for the morphofunctional restoration of peripheral nerves in painful sensitive-motor-type diabetic neuropathy and the manifestations of ischemic neuritis.

摘要翻译： 本发明涉及人类药物和表皮生长因子（EGF）用于制备药物组合物的用途，所述药物组合物通过渗透到神经节和/或树干的周围而在疼痛的感觉运动神经病变中用于外周神经的形态功能恢复 以及缺血性神经炎的表现。 本发明还包括含有EGF的组合物，其可以与麻醉剂或止痛剂一起配制或包封在微球体中，以及其用于在疼痛敏感性运动型糖尿病性神经病变中的周围神经的形态功能恢复和缺血性神经炎的表现的用途。

公开(公告)号：US20100136062A1

公开(公告)日：2010-06-03

申请号：US12443837

申请日：2007-10-01

申请人： Jose Ignacio Fernandez Montequin ,  Luis Saturnino Herrera Martinez ,  Jorge Amador Berlanga Acosta ,  Diana Garcia Del Barco Herrera ,  Danay Cibrian Vera ,  Gerardo Enrique Guillen Nieto ,  Raimundo Ubieta Gomez ,  Sonia Gonzalez Blanco ,  Vivian Maria Saez Martinez

发明人： Jose Ignacio Fernandez Montequin ,  Luis Saturnino Herrera Martinez ,  Jorge Amador Berlanga Acosta ,  Diana Garcia Del Barco Herrera ,  Danay Cibrian Vera ,  Gerardo Enrique Guillen Nieto ,  Raimundo Ubieta Gomez ,  Sonia Gonzalez Blanco ,  Vivian Maria Saez Martinez

IPC分类号： A61K38/18 ,  C07K14/485 ,  A61K9/00 ,  A61P25/02

CPC分类号： A61K38/1808 ,  A61K9/16 ,  C07K14/485 ,  Y10S930/12

摘要： The invention relates to human medicine and to the use of epidermal growth factor (EGF) for preparing a pharmaceutical composition which is administered by infiltration into the periphery of nerve ganglia and/or trunks for the morphofunctional restoration of peripheral nerves in painful sensory-motor neuropathy as well as manifestations of ischemic neuritis. The invention also includes a composition containing EGF which can be formulated together with anaesthetics or analgesics or encapsulated in microspheres and to the use thereof for the morphofunctional restoration of peripheral nerves in painful sensitive-motor-type diabetic neuropathy and the manifestations of ischemic neuritis.

摘要翻译： 本发明涉及人类药物和表皮生长因子（EGF）用于制备药物组合物的用途，所述药物组合物通过渗透到神经节和/或树干的周围而在疼痛的感觉运动神经病变中用于外周神经的形态功能恢复 以及缺血性神经炎的表现。 本发明还包括含有EGF的组合物，其可以与麻醉剂或止痛剂一起配制或包封在微球体中，以及其用于在疼痛敏感性运动型糖尿病性神经病变中的周围神经的形态功能恢复和缺血性神经炎的表现的用途。

公开(公告)号：US20120308615A1

公开(公告)日：2012-12-06

申请号：US13498842

申请日：2010-09-28

申请人： Julio César Aguilar Rubido ,  Yadira Lobaina Mato ,  Dunia Hernández Inguanzo ,  Heidy Trujillo Pérez ,  Freya de los Milagros Freyre Almeida ,  Verena Lucila Muzio González ,  Eduardo Pénton Arias ,  Sonia Gonzalez Blanco ,  Raimundo Ubieta Gómez ,  Gerardo Enrique Guillén Nieto ,  Luis Saturnino Herrera Martinez

发明人： Julio César Aguilar Rubido ,  Yadira Lobaina Mato ,  Dunia Hernández Inguanzo ,  Heidy Trujillo Pérez ,  Freya de los Milagros Freyre Almeida ,  Verena Lucila Muzio González ,  Eduardo Pénton Arias ,  Sonia Gonzalez Blanco ,  Raimundo Ubieta Gómez ,  Gerardo Enrique Guillén Nieto ,  Luis Saturnino Herrera Martinez

IPC分类号： A61K39/29 ,  A61P31/14 ,  C12N5/0781 ,  C12N5/0786 ,  C12N5/0784 ,  A61K9/14 ,  C12N5/078

CPC分类号： A61K9/145 ,  A61K9/10 ,  A61K39/12 ,  A61K39/292 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55505 ,  C12N2730/10134

摘要： The present invention is related with the field of the therapeutic immunization, specifically with the employment of a new formulation of antigens of the Hepatitis B Virus (HBV) for the cellular stimulation. The formulation is formed by the surface antigens (HBsAg) precipitated in suspension and the nucleocapsid (HBcAg) of the HBV. The formulation contains these antigens like suspended particles of sizes less than 500 nm and higher than 500 nm, in a mixture where the proportion among the particles of the mentioned sizes is among 50%-50% and 80%-20%, respectively. The selection of a range of sizes of particles allows that the levels of stimulation of several cellular types are maximized. Additionally, a cellular stimulation method is described with this formulation, and the later passive immunization of patients with chronic Hepatitis B, based on the maximum stimulation in vivo or in vitro using heterologous or autologous cells (dendritic cells, B cells and macrophages). The cells stimulated with this formulation are transferred to patients chronically infected with the HBV.

摘要翻译： 本发明涉及治疗性免疫领域，特别是使用乙型肝炎病毒（HBV）抗原的新配方用于细胞刺激。 该制剂由悬浮液中沉淀的表面抗原（HBsAg）和HBV的核衣壳（HBcAg）形成。 在上述尺寸的颗粒中的比例分别为50％-50％至80％-20％的混合物中，该制剂含有这些抗原，如尺寸小于500nm且高于500nm的悬浮颗粒。 颗粒尺寸范围的选择使得几种细胞类型的刺激水平最大化。 另外，根据体内或体外使用异源或自体细胞（树突状细胞，B细胞和巨噬细胞）的最大刺激，用该配方描述细胞刺激方法，以及慢性乙型肝炎患者随后的被动免疫。 用该制剂刺激的细胞转移到长期感染HBV的患者。

公开(公告)号：US20140112976A1

公开(公告)日：2014-04-24

申请号：US14005855

申请日：2012-03-21

申请人： María del Carmen Abrahantes Pérez ,  Glay Chinea Santiago ,  Eduardo Martínez Díaz ,  Hilda Elisa Garay Perez ,  Osvaldo Reyes Acosta ,  Ernesto Lopez Mola ,  Cruz Matilde Lopez Abad ,  Sonia Gonzalez Blanco

发明人： María del Carmen Abrahantes Pérez ,  Glay Chinea Santiago ,  Eduardo Martínez Díaz ,  Hilda Elisa Garay Perez ,  Osvaldo Reyes Acosta ,  Ernesto Lopez Mola ,  Cruz Matilde Lopez Abad ,  Sonia Gonzalez Blanco

IPC分类号： A61K38/12 ,  A61K31/4025 ,  A61K45/06 ,  C07K7/64

CPC分类号： A61K38/12 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/5031 ,  A61K31/4025 ,  A61K38/00 ,  A61K45/06 ,  A61K47/60 ,  C07K7/06 ,  C07K7/08 ,  C07K7/64

摘要： The present invention comprises cyclic peptides bearing antitumor and antiangiogenic properties, as well as their corresponding pharmaceutically-suitable salts and also pharmaceutical compositions containing it. These cyclic peptides are used to prepare medicines for human and/or veterinary therapeutics, and additionally in diagnosis. These compounds can be used to detect, monitor and/or control a range of cellular proliferation-related disorders, such as oncological diseases and undesired angiogenesis. Moreover, they can be included as part of controlled release systems, and used more precisely in the field of nanobiotechnology, either because of their self-assembly capacity or as part of other systems.

摘要翻译： 本发明包括具有抗肿瘤和抗血管生成特性的环肽，以及它们相应的药学上合适的盐以及含有它的药物组合物。 这些环肽用于制备用于人和/或兽医治疗剂的药物，另外用于诊断。 这些化合物可用于检测，监测和/或控制一系列细胞增殖相关疾病，例如肿瘤疾病和不期望的血管生成。 此外，它们可以作为控制释放系统的一部分进行纳入，并且在纳米生物技术领域更加精确地使用，无论是由于其自组装能力还是作为其他系统的一部分。

公开(公告)号：US20090297547A1

公开(公告)日：2009-12-03

申请号：US12295436

申请日：2007-03-29

申请人： Rolando Pajon Feyt ,  Gretel Sardinas Garcia ,  Darien Garcia Diaz ,  Sonia Gonzalez Blanco

发明人： Rolando Pajon Feyt ,  Gretel Sardinas Garcia ,  Darien Garcia Diaz ,  Sonia Gonzalez Blanco

IPC分类号： A61K39/12 ,  C12Q1/68 ,  G01N33/53 ,  A61K38/16 ,  C07K14/22

CPC分类号： A61K39/095 ,  A61K2039/6068 ,  C07K14/22

摘要： The present invention is related to field of medicine, particularly to the development of pharmaceutical formulation containing NMB0938 protein. Formulation described in this invention is able to confer protection against different diseases caused or not by pathogenic agents. NMB0938 protein was identified as a Neisseria meningitidis outer membrane vesicle (OMV) component, and it was obtained through recombinant DNA technology being its immunogenicity and protective activity evaluated in animal models. Due to the high level of conservation the NMB0938 coding gene has shown, pharmaceutical compositions containing this protein have a high value as inducers of a cross-reactive immune response. Formulation presented in this invention is applicable to the field of human medicine.

摘要翻译： 本发明涉及药物领域，特别涉及含有NMB0938蛋白质的药物制剂的开发。 本发明描述的制剂能够赋予针对由病原体引起或不由病原体引起的不同疾病的保护作用。 NMB0938蛋白被鉴定为脑膜炎奈瑟氏球菌外膜囊泡（OMV）组分，通过重组DNA技术获得其在动物模型中评估的免疫原性和保护活性。 由于NMB0938编码基因的保守程度高，含有这种蛋白质的药物组合物具有高价值作为交叉反应性免疫应答的诱导剂。 本发明提出的制剂适用于人类医学领域。

公开(公告)号：US09375459B2

公开(公告)日：2016-06-28

申请号：US14005855

申请日：2012-03-21

申请人： María del Carmen Abrahantes Pérez ,  Glay Chinea Santiago ,  Eduardo Martínez Diaz ,  Hilda Elisa Garay Pérez ,  Osvaldo Reyes Acosta ,  Ernesto Lopez Mola ,  Cruz Matilde Lopez Abad ,  Sonia Gonzalez Blanco

发明人： María del Carmen Abrahantes Pérez ,  Glay Chinea Santiago ,  Eduardo Martínez Diaz ,  Hilda Elisa Garay Pérez ,  Osvaldo Reyes Acosta ,  Ernesto Lopez Mola ,  Cruz Matilde Lopez Abad ,  Sonia Gonzalez Blanco

IPC分类号： A61K38/12 ,  A61K31/4025 ,  A61K45/06 ,  C07K7/64 ,  C07K7/06 ,  C07K7/08 ,  A61K47/48 ,  A61K38/00 ,  A61K9/00 ,  A61K9/127 ,  A61K9/50

CPC分类号： A61K38/12 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/5031 ,  A61K31/4025 ,  A61K38/00 ,  A61K45/06 ,  A61K47/60 ,  C07K7/06 ,  C07K7/08 ,  C07K7/64

摘要： The present invention comprises cyclic peptides bearing antitumor and antiangiogenic properties, as well as their corresponding pharmaceutically-suitable salts and also pharmaceutical compositions containing it. These cyclic peptides are used to prepare medicines for human and/or veterinary therapeutics, and additionally in diagnosis. These compounds can be used to detect, monitor and/or control a range of cellular proliferation-related disorders, such as oncological diseases and undesired angiogenesis. Moreover, they can be included as part of controlled release systems, and used more precisely in the field of nanobiotechnology, either because of their self-assembly capacity or as part of other systems.

摘要翻译： 本发明包括具有抗肿瘤和抗血管生成特性的环肽，以及它们相应的药学上合适的盐以及含有它的药物组合物。 这些环肽用于制备用于人和/或兽医治疗剂的药物，另外用于诊断。 这些化合物可用于检测，监测和/或控制一系列细胞增殖相关疾病，例如肿瘤疾病和不期望的血管生成。 此外，它们可以作为控制释放系统的一部分进行纳入，并且在纳米生物技术领域更加精确地使用，无论是由于其自组装能力还是作为其他系统的一部分。

公开(公告)号：US20100129387A1

公开(公告)日：2010-05-27

申请号：US12295198

申请日：2007-03-29

申请人： Rolando Pajón Feyt ,  Karem Cobas Acosta ,  Yasser Perera Negrin ,  Gretel Sardiñas Garcia ,  Darién Garcia Diaz ,  Sonia Gonzalez Blanco

发明人： Rolando Pajón Feyt ,  Karem Cobas Acosta ,  Yasser Perera Negrin ,  Gretel Sardiñas Garcia ,  Darién Garcia Diaz ,  Sonia Gonzalez Blanco

IPC分类号： A61K39/00 ,  C07K14/00 ,  G01N33/53 ,  A61P31/04 ,  A61P37/04

CPC分类号： A61K38/16 ,  A61K39/095 ,  C07K14/22 ,  Y10T436/143333

摘要： The present invention is related to field of medicine, particularly to the development of pharmaceutical formulation containing NMB0606 protein. Formulation described in this invention is able to confer protection against different diseases caused or not by pathogenic agents. NMB0606 protein was identified as a Neisseria meningitidis outer membrane vesicle (OMV) component, and it was obtained through recombinant DNA technology being its immunogenicity and protective activity evaluated in animal models. Due to the high level of conservation the NMB0606 coding gene has shown, pharmaceutical composition containing this protein has a high value as inducers of a cross-reactive immune response. Formulation presented in this invention is applicable to the field of human medicine.

摘要翻译： 本发明涉及药物领域，特别涉及含有NMB0606蛋白质的药物制剂的开发。 本发明描述的制剂能够赋予针对由病原体引起或不由病原体引起的不同疾病的保护作用。 NMB0606蛋白被鉴定为脑膜炎奈瑟氏球菌外膜囊泡（OMV）组分，通过重组DNA技术获得其在动物模型中评估的免疫原性和保护活性。 由于NMB0606编码基因的高度保守性，含有这种蛋白质的药物组合物作为交叉反应性免疫反应的诱导剂具有很高的价值。 本发明提出的制剂适用于人类医学领域。

公开(公告)号：US20090208521A1

公开(公告)日：2009-08-20

申请号：US12097895

申请日：2006-12-28

申请人： Rolando Pajon Feyt ,  Gretel Sardinas Garcia ,  Agustin Lage Castellanos ,  Daniel Yero Corona ,  Darien Garcia Diaz ,  Sonia Gonzalez Blanco

发明人： Rolando Pajon Feyt ,  Gretel Sardinas Garcia ,  Agustin Lage Castellanos ,  Daniel Yero Corona ,  Darien Garcia Diaz ,  Sonia Gonzalez Blanco

IPC分类号： A61K39/095 ,  A61K38/16 ,  A61P37/04

CPC分类号： A61K39/095 ,  A61K39/385 ,  A61K2039/55555 ,  A61K2039/6068 ,  C07K14/22 ,  C12Q1/6883

摘要： The present invention is related to field of medicine, particularly to the development of pharmaceutical formulations containing NMA0939 protein. Formulations described in this invention are able to confer protection against different diseases caused or not by pathogenic agents. NMA0939 protein was identified as a Neisseria meningitidis outer membrane vesicle component, and it was obtained through recombinant DNA technology being its immunogenicity and protective activity evaluated in animal models. Due to the high level of conservation the NMA0939 coding gene has shown, pharmaceutical compositions containing this protein have a high value as inducers of a cross-reactive immune response. Formulations presented in this invention are applicable to the field of human medicine.

摘要翻译： 本发明涉及药物领域，特别涉及含有NMA0939蛋白质的药物制剂的开发。 在本发明中描述的制剂能够赋予针对由病原体引起或不由病原体引起的不同疾病的保护作用。 NMA0939蛋白被鉴定为脑膜炎奈瑟氏球菌外膜囊泡成分，通过重组DNA技术获得其在动物模型中评估的免疫原性和保护活性。 由于NMA0939编码基因表现出高水平的保守性，含有这种蛋白质的药物组合物作为交叉反应性免疫应答的诱导剂具有很高的价值。 本发明提出的制剂适用于人类医学领域。

公开(公告)号：US20070166333A1

公开(公告)日：2007-07-19

申请号：US10577000

申请日：2004-11-03

申请人： Olivia Niebla Perez ,  Rolando Pajon Feyt ,  Sonia Gonzalez Blanco ,  Alejandro Martin Dunn ,  Maite Delgado Espina ,  Hilda Garay Perez ,  Gerardo Guillen Nieto

发明人： Olivia Niebla Perez ,  Rolando Pajon Feyt ,  Sonia Gonzalez Blanco ,  Alejandro Martin Dunn ,  Maite Delgado Espina ,  Hilda Garay Perez ,  Gerardo Guillen Nieto

IPC分类号： A61K39/095 ,  C12N15/74 ,  C12N1/21

CPC分类号： C07K14/22 ,  A61K39/00

摘要： Method for the insertion of protein antigens, of recombinant or synthetic origin, in outer membrane vesicles of Gram-negative bacteria without disruption of the vesicle structure, therefore maintaining the immunogenicity and immunostimulatory properties of said vesicles, and with the reported advantage that the immune response generated against the incorporated antigen is superior to the one generated when the antigen is administered alone. The resultant vaccine formulations are useful to increase protective capacity of existing vaccines and allow to extend it against different pathogens, in diseases of bacterial, viral, cancerous or other etiology. The referred formulations are applicable in the pharmaceutical industry as vaccines for therapeutic and preventive use in humans.

摘要翻译： 在革兰氏阴性细菌的外膜囊泡中插入重组或合成来源的蛋白质抗原的方法，而不破坏囊泡结构，从而保持所述囊泡的免疫原性和免疫刺激性质，并且报告的优点是免疫应答 针对所掺入的抗原产生的抗原优于单独施用抗原时产生的抗原。 所得的疫苗制剂可用于增加现有疫苗的保护能力，并允许其在细菌，病毒，癌性或其它病因学疾病中扩展到不同的病原体。 所提及的制剂在制药工业中可用作人类治疗和预防用途的疫苗。

公开(公告)号：US20100172931A1

公开(公告)日：2010-07-08

申请号：US12664278

申请日：2008-06-16

申请人： Rolando Pajon Feyt ,  Olivia Niebla Perez ,  Gretel Sardinas Garcia ,  Sonia Gonzalez Blanco ,  Darien Garcia Diaz ,  Evelin Caballero Menendez ,  Karem Cobas Acosta

发明人： Rolando Pajon Feyt ,  Olivia Niebla Perez ,  Gretel Sardinas Garcia ,  Sonia Gonzalez Blanco ,  Darien Garcia Diaz ,  Evelin Caballero Menendez ,  Karem Cobas Acosta

IPC分类号： A61K39/095 ,  C07K14/22 ,  A61K39/385 ,  C12Q1/02 ,  A61P31/04

CPC分类号： A61K39/095 ,  A61K2039/55583

摘要： The present invention is related to field of medicine, particularly to the development of pharmaceutical composition containing the NMB1796 protein. The composition described in this invention are able to confer protection against different diseases caused or not by pathogenic agents. The NMB1796 protein was identified as a Neisseria meningitidis outer membrane vesicle (OMV) component, and it was obtained through recombinant DNA technology being its immunogenicity and protective activity evaluated in animal models. Due to the high level of conservation that the NMB1796 coding gene has shown, pharmaceutical compositions containing this protein have a high value as inducers of a cross-reactive immune response. The composition presented in this invention is applicable to the field of human medicine.

摘要翻译： 本发明涉及药物领域，特别涉及含有NMB1796蛋白质的药物组合物的开发。 本发明中描述的组合物能够赋予针对由病原体引起或不由病原体引起的不同疾病的保护作用。 NMB1796蛋白被鉴定为脑膜炎奈瑟氏球菌外膜囊泡（OMV）组分，通过重组DNA技术获得其在动物模型中评估的免疫原性和保护活性。 由于NMB1796编码基因表现出高度的保守性，含有该蛋白质的药物组合物具有作为交叉反应性免疫应答诱导剂的高价值。 本发明提供的组合物可应用于人类医学领域。